Pentixapharm H1 FY26 net loss narrows to EUR 6.92 million

• Pentixapharm reported a H1 net loss attributable to shareholders that narrowed to EUR 6.92 million, or EUR 0.28 per share, from EUR 8.4 million.
• EBIT improved to a loss of EUR 6.62 million from EUR 8.67 million, while revenue fell to no revenue from EUR 38,000.
• R&D materials and external services costs dropped to EUR 1.28 million from EUR 2.79 million; other operating income slid to EUR 74,000 from EUR 320,000.
• Cash and cash equivalents declined to EUR 3.59 million at June 30 from EUR 4.62 million at year-end, despite EUR 4 million in convertible bond proceeds.
• FDA cleared the start of US studies for the panda Phase 3 diagnostic program and the penthera Phase 1 hemato-oncology program; 2026 loss outlook stayed at about EUR 21.6 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.